We advised the sales agents on the offering

Davis Polk advised the sales agents in connection with the SEC-registered at-the-market offering by Personalis, Inc. of its common stock for up to an aggregate amount of $150 million. The common stock is listed on the Nasdaq Global Market under the ticker symbol “PSNL.”

Personalis develops, markets and sells advanced cancer genomic testing services. Its tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy and uncover insights for therapy selection. It also provides whole exome sequencing services for other diagnostic companies and whole genome sequencing services for population sequencing initiatives.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Michael Kostukovsky and Matthew Kenney. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post